Skip to content

A real-world study for the efficacy and safety of Monoammonium Glycyrrhizinate and Cysteine and Sodium Chloride Injection in patients with perioperative liver injury

A real-world study for the efficacy and safety of Monoammonium Glycyrrhizinate and Cysteine and Sodium Chloride Injection in patients with perioperative liver injury

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029206
Enrollment
Unknown
Registered
2020-01-18
Start date
2020-01-06
Completion date
Unknown
Last updated
2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative liver injury

Interventions

Case series:None

Sponsors

The First Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years old, male or female; 2. Patients who need to undergo hepatectomy (resection volume is limited to three or more liver segments); 3. Participate voluntarily and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Intraoperative hepatectomy was not performed; 2. Complicated with heart, lung, renal insufficiency and other systemic diseases; 3. Patients with severe hypokalemia and hypernatremia; 4. Those who are allergic to the ingredients of glycyrrhizin preparations; 5. Pregnancy and lactation; 6. Participants in other clinical trials within 3 months; 7. Plan to use liver-protecting drugs with the same or similar composition as monoammonium glycyrrhizinate and sodium chloride injection; 8. The researcher considered that the patient was not suitable for inclusion in this study.

Design outcomes

Primary

MeasureTime frame
The total recovery rate of liver function in subjects receiving hepatoprotective therapy after hepatectomy;

Secondary

MeasureTime frame
The total effective rate of liver function recovery in different primary patients;The total recovery rate of liver function using different combinations of hepatoprotective drugs;The total effective rate of liver function recovery in different surgical methods;

Countries

China

Contacts

Public ContactBao-Gang Peng

The First Affiliated Hospital of Sun Yat-sen University

pengbg@mail.sys.edu.cn+86 13922276105

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026